Skip to main content

Antonio Rothfuchs Group

Mycobacteria cause serious infections in humans, especially the intracellular bacillus Mycobacterium tuberculosis, which is a leading cause of death due to infection. We study the immune response to mycobacteria, especially the initiation of CD4+ T-cell responses. We are also interested in sampling M. tuberculosis from air and in novel therapies against this microorganism.

Dendritic cell responses to mycobacteria

The arrival of mycobacteria in the draining lymph node is necessary for initiating protective, T-cell responses against the bacilli, but this remains poorly understood for both M. tuberculosis and M. bovis Bacille Calmette-Guérin (BCG), the live tuberculosis vaccine. Upon microbial encounter, Dendritic cells at the site of infection become activated and migrate to the draining lymph node where they activate naïve T cells. We are interested in the role played by different Dendritic cells in this process, including the mechanisms by which Dendritic cells mobilize to the lymph node in response to BCG, their ability to ferry BCG to the lymph node, and to trigger the activation CD4+ T cells therein. Understanding the above is critical for deciphering the basis of productive T-cell responses and for advancing our capacity to improve BCG and other vaccines of low-to-modest efficacy that rely on such responses.

Development of a bio-aerosol sampler for M. tuberculosis

We know very little about M. tuberculosis in aerosol droplets, the transmissible form of the pathogen. This is largely due to the lack of adequate detection technology for sampling M. tuberculosis from air. Collecting bacilli from air would advance our understanding of transmission by enabling the subsequent analysis of the transmissible form of the organism. This in turn can be used to deploy tools of impact for intervention of tuberculosis and also to reduce the risk of transmission in high-risk settings. We are developing a sampling device that uses ionization technology to capture airborne mycobacteria. In a uniquely tailored aerobiology chamber, we are testing and refining this device for aerosol sampling of mycobacteria, hoping to create a prototype suitable for field trials.

Antisense-based treatment of tuberculosis

In collaboration with Sarepta Therapeutics, a leader in the field of antisense-based RNA therapeutics, we are evaluating the effect of novel, antisense phosphorodiamidate morpholino oligomers in blocking mycobacterial replication. Similar compounds are also being tested to modulate and consequently improve the immune response to mycobacteria. This technology may lead to the development of new antimicrobials and cell-based therapy against tuberculosis.

Selected publications

29772005

28276533

27768071

26440518

26819205

25817335

22156594

21596592

20389020

19454688

18261937

17785780

Group Members

Juliana AggioAnknuten

juliana.aggio@ki.se

08-542 852 52

Antonio Gigliotti RothfuchsForskare

Antonio.Rothfuchs@ki.se

08-524 852 52

Sören HartmannAnknuten

soren.hartmann@ki.se

Veronika KrmeskaDoktorand, Forskarstuderande

veronika.krmeska@ki.se

Nuno Ramos Rufino de SousaForskningsassistent, UF

nuno.ramos.rufino.de.sousa@ki.se

Lei ShenAnknuten, Postdoc

lei.shen@ki.se

Afifa SultanaAnknuten

afifa.sultana@ki.se

Former Group Members

Vishnu Priya Bollampalli, Defended PhD thesis April 2017
Jintao Guo, postdoc, 2016-2017
Sara Fernandez Leon, research assistant, 2016-2017
Livia Harumi Yamashiro, visiting PhD student from UFSC Brazil, 2014